GeneDx Can Sequence a Genome. It Can't Get Paid for It.

GeneDx announces a study today showing rapid genome sequencing found genetic diagnoses in 35% of general inpatients at Seattle Children's — 43% on regular hospital wards, 63% in children with faltering growth. Nobody traditionally sends those kids for genetic testing. The clinical case for broader sequencing looks solid.

The problem for GeneDx isn't clinical. It's financial. And it's been there for months.

The number that matters: GeneDx collects about 32 cents of every dollar billed for whole genome tests done outside the hospital. Their long-term target is 70%. In the NICU, they collect 100%. Nobody argues about sequencing a critically ill infant. But when a general pediatrician orders a genome test for a child who's just slow to develop, the insurance company often denies it. Or delays it. Or GeneDx doesn't have the billing infrastructure to fight the denial.

Management called it a revenue cycle management problem on the last earnings call. It's a polite way of saying they run tests and don't get paid for them.

The consequences show up in the financials. Revenue grew 11% to $114.4 million in the second quarter of 2026. Volume grew 32%. Different growth rates for a reason — more tests are being done, but the average amount actually collected per test has been slipping. The blended reimbursement rate was $3,258 per test, roughly flat quarter-over-quarter. That includes NICU tests where collection is perfect. Strip those out and the outpatient collection is well below where it needs to be.

GAAP gross margin sits at 70%. Strong, until you look further down. Operating expenses were $96 million — 84% of revenue. The company lost $17.7 million in the quarter. On an adjusted basis, they made $0.4 million. Management called it a return to profitability, one quarter earlier than planned. It's technically true and practically thin.

For the trailing twelve months, free cash flow is negative $76 million. The company had $60 million in cash and $237 million in debt as of late June. In August they amended their credit facility with Blackstone, adding another $50 million in borrowing capacity. That feels like a company running tests it can't get paid for, spending cash to grow volume it can't fully bill, and borrowing to bridge the gap.

Here's what the Seattle study doesn't address. Most of those 1,000-plus children were tested in a hospital setting, where the hospital absorbs the sequencing cost and doesn't send a bill to the family's insurer the way an outpatient test does. The study proves sequencing works on general wards. It doesn't prove insurers will pay for it when it's ordered from those wards.

GeneDx knows this. Management has identified four levers: managing the mix between exome and genome tests, expanding payer coverage, building payer-specific billing workflows, and investing in systems for revenue cycle management. Commercial genome coverage expanded from 47% to 87% of commercial lives in one quarter, driven by a new Carelon policy covering roughly 56 million lives. Medicaid now covers sequencing in 39 states. Real steps.

But collection rates of 32% don't jump to 70% because coverage expands on paper. There's a gap between what insurance says it covers and what actually gets paid. That gap is where the money lives or dies for this business.

Full-year 2026 guidance is $475 to $490 million in revenue with adjusted profitability. Roughly $120 million per quarter. At a 70% adjusted gross margin, that's about $84 million of gross profit per quarter against roughly $80 million in operating expenses. The path to profitability is maybe $4 million a quarter — a margin that can disappear from one bad billing cycle or one payer denial trend.

The stock trades around $86, for a market cap of $2.6 billion. It's up 42% over the last month and down 34% year-to-date from a 52-week high of $171. The market is trying to figure out the same thing.

What would change your mind about this company? Not another study. The clinical evidence is already there. What would change it is watching the collection rate move. If GeneDx gets from 32% to 50% and then to 60% over the next two quarters, the math starts working. If it stays flat through 2027 despite the coverage expansions, then the business model has a structural mismatch — great tests, great margins, and an inability to collect from the people who order the tests.

The question for anyone watching this stock isn't whether genome sequencing should be done in general hospitals. The Seattle study answers that. The question is whether GeneDx can build the unglamorous billing infrastructure to get paid for it. That's not a technology problem. It's an operations problem. And operations problems don't get solved by announcements.